Health
Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy – News-Medical.net
Avacta Group plc, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co.Ltd and AffyXell Therapeutics.
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell Therapeutics, the joint venture established in South Korea by the two companies, to develop stem cell treatments incorporating Avacta’s neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future globa…
-
Business23 hours agoWhy this fantastic blue chip ASX 200 share could rise 20%
-
General22 hours agoAlbanese government to freeze construction code until 2029, fast-track housing approvals
-
Noosa News14 hours agoDog daycare program a TikTok hit for helping disabled find work, friends
-
General16 hours agoPhotographers reveal iconic image of Gough Whitlam and Vincent Lingiari was posed on Wave Hill Walk-Off anniversary